These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31810818)

  • 1. Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46).
    Panizza BJ; de Souza P; Cooper A; Roohullah A; Karapetis CS; Lickliter JD
    EBioMedicine; 2019 Dec; 50():433-441. PubMed ID: 31810818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors.
    Miller J; Campbell J; Blum A; Reddell P; Gordon V; Schmidt P; Lowden S
    Front Vet Sci; 2019; 6():106. PubMed ID: 31111038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46).
    De Ridder TR; Campbell JE; Burke-Schwarz C; Clegg D; Elliot EL; Geller S; Kozak W; Pittenger ST; Pruitt JB; Riehl J; White J; Wiest ML; Johannes CM; Morton J; Jones PD; Schmidt PF; Gordon V; Reddell P
    J Vet Intern Med; 2021 Jan; 35(1):415-429. PubMed ID: 32542733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate.
    Barnett CME; Broit N; Yap PY; Cullen JK; Parsons PG; Panizza BJ; Boyle GM
    Invest New Drugs; 2019 Feb; 37(1):1-8. PubMed ID: 29667135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the Intratumoural Anticancer Drug Tigilanol Tiglate in Two Horses.
    De Ridder T; Ruppin M; Wheeless M; Williams S; Reddell P
    Front Vet Sci; 2020; 7():639. PubMed ID: 33033726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
    Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
    Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence-free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate.
    Jones PD; Campbell JE; Brown G; Johannes CM; Reddell P
    J Vet Intern Med; 2021 Jan; 35(1):451-455. PubMed ID: 33350511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenic oncolysis by tigilanol tiglate.
    Pol JG; Lizarralde-Guerrero M; Kroemer G
    Oncoimmunology; 2024; 13(1):2360230. PubMed ID: 38812571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
    Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
    Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate.
    Brown GK; Campbell JE; Jones PD; De Ridder TR; Reddell P; Johannes CM
    Front Vet Sci; 2021; 8():675804. PubMed ID: 34513966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical synthesis of the therapeutic leads tigilanol tiglate and its analogues.
    Wender PA; Gentry ZO; Fanelli DJ; Luu-Nguyen QH; McAteer OD; Njoo E
    Nat Chem; 2022 Dec; 14(12):1421-1426. PubMed ID: 36192432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
    Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
    Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wound formation, wound size, and progression of wound healing after intratumoral treatment of mast cell tumors in dogs with tigilanol tiglate.
    Reddell P; De Ridder TR; Morton JM; Jones PD; Campbell JE; Brown G; Johannes CM; Schmidt PF; Gordon V
    J Vet Intern Med; 2021 Jan; 35(1):430-441. PubMed ID: 33438258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianes.
    Cullen JK; Boyle GM; Yap PY; Elmlinger S; Simmons JL; Broit N; Johns J; Ferguson B; Maslovskaya LA; Savchenko AI; Mirzayans PM; Porzelle A; Bernhardt PV; Gordon VA; Reddell PW; Pagani A; Appendino G; Parsons PG; Williams CM
    Sci Rep; 2021 Jan; 11(1):207. PubMed ID: 33420238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate.
    Brown GK; Finlay JR; Straw RC; Ziea JY; Leung B; O'Connell K; Thomson MJ; Campbell JE; Jones PD; Reddell P
    Front Vet Sci; 2022; 9():1003165. PubMed ID: 36387404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer.
    Hanna N; Ohana P; Konikoff FM; Leichtmann G; Hubert A; Appelbaum L; Kopelman Y; Czerniak A; Hochberg A
    Cancer Gene Ther; 2012 Jun; 19(6):374-81. PubMed ID: 22498722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
    Ahn MJ; Kim DW; Cho BC; Kim SW; Lee JS; Ahn JS; Kim TM; Lin CC; Kim HR; John T; Kao S; Goldman JW; Su WC; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; Yang JC
    Lancet Respir Med; 2017 Nov; 5(11):891-902. PubMed ID: 29056570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.